Literature DB >> 22036880

Bioreducible polyethylenimine-delivered siRNA targeting human telomerase reverse transcriptase inhibits HepG2 cell growth in vitro and in vivo.

Wei Xia1, Peijun Wang, Chao Lin, Zhuoquan Li, Xiaolong Gao, Guoliang Wang, Xiaohu Zhao.   

Abstract

One new siRNA sequence was found efficient for human telomerase reverse transcriptase (hTERT) gene silencing in vitro in five types of human cancer cells. Then, a biodegradable polyethylenimine containing multiple disulfide bonds (SS-PEI) was successfully applied as a potent non-viral carrier for intracellular delivery of the hTERT siRNA in vitro and in vivo. The SS-PEI could strongly bind siRNA to form nano-sized and positively-charged complexes, but which were readily destabilized to sufficiently release siRNA in a reducing environment. Transfection experiments showed that the complexes of SS-PEI/hTERT siRNA were able to transfect HepG2 cells in vitro, inducing reduced levels of hTERT mRNA and hTERT protein, decreased telomerase activity, cell growth inhibition and significant cell apoptosis. Besides, treatment with the complexes of SS-PEI/hTERT siRNA could inhibit HepG2 tumor growth in a xenograft mouse model. Importantly, the SS-PEI revealed relatively low cytotoxicity in vitro and at an appropriate dose had no adverse effect on liver and kidney functions in vivo. The results of this study indicate that SS-PEI/siRNA-induced hTERT gene silencing provides a promising method for human cancer gene therapy. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22036880     DOI: 10.1016/j.jconrel.2011.10.011

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  14 in total

1.  Functional properties and biodistribution of poly(triethylenetetramine/cystamine bisacrylamide) and poly(triethylenetetramine/cystamine bisacrylamide)- poly(ethylene glycol) mixtures formed with nucleic acid.

Authors:  Jonathan H Brumbach; Yong Won Lee; Sung Wan Kim; James W Yockman
Journal:  J Control Release       Date:  2012-01-20       Impact factor: 9.776

2.  Structural evolution of environmentally responsive cationic liposome-DNA complexes with a reducible lipid linker.

Authors:  Rahau S Shirazi; Kai K Ewert; Bruno F B Silva; Cecilia Leal; Youli Li; Cyrus R Safinya
Journal:  Langmuir       Date:  2012-06-06       Impact factor: 3.882

Review 3.  Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs.

Authors:  Fang Liu; Chunfang Wang; Yuantao Gao; Xiao Li; Feng Tian; Yongtao Zhang; Mingyang Fu; Pengfei Li; Yali Wang; Fei Wang
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

Review 4.  Bioreducible polycations in nucleic acid delivery: past, present, and future trends.

Authors:  David Oupický; Jing Li
Journal:  Macromol Biosci       Date:  2014-03-28       Impact factor: 4.979

5.  Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-α RNA interference for IBD therapy.

Authors:  Bo Xiao; Hamed Laroui; Saravanan Ayyadurai; Emilie Viennois; Moiz A Charania; Yuchen Zhang; Didier Merlin
Journal:  Biomaterials       Date:  2013-06-29       Impact factor: 12.479

Review 6.  Delivery strategies and potential targets for siRNA in major cancer types.

Authors:  So Jin Lee; Min Ju Kim; Ick Chan Kwon; Thomas M Roberts
Journal:  Adv Drug Deliv Rev       Date:  2016-05-31       Impact factor: 15.470

7.  Disulfide Bridging Strategies in Viral and Nonviral Platforms for Nucleic Acid Delivery.

Authors:  Kingshuk Dutta; Ritam Das; Jewel Medeiros; S Thayumanavan
Journal:  Biochemistry       Date:  2021-01-11       Impact factor: 3.162

8.  Theranostic nanoparticles based on bioreducible polyethylenimine-coated iron oxide for reduction-responsive gene delivery and magnetic resonance imaging.

Authors:  Dan Li; Xin Tang; Benjamin Pulli; Chao Lin; Peng Zhao; Jian Cheng; Zhongwei Lv; Xueyu Yuan; Qiong Luo; Haidong Cai; Meng Ye
Journal:  Int J Nanomedicine       Date:  2014-07-10

9.  Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.

Authors:  Patrick J Killela; Christopher J Pirozzi; Patrick Healy; Zachary J Reitman; Eric Lipp; B Ahmed Rasheed; Rui Yang; Bill H Diplas; Zhaohui Wang; Paula K Greer; Huishan Zhu; Catherine Y Wang; Austin B Carpenter; Henry Friedman; Allan H Friedman; Stephen T Keir; Jie He; Yiping He; Roger E McLendon; James E Herndon; Hai Yan; Darell D Bigner
Journal:  Oncotarget       Date:  2014-03-30

10.  Silencing of the hTERT gene by shRNA inhibits colon cancer SW480 cell growth in vitro and in vivo.

Authors:  Ai-Qun Liu; Lian-Ying Ge; Xiao-Ling Lu; Xiao-Ling Luo; Yan-Ling Cai; Xing-Qing Ye; Fang-Fang Geng
Journal:  PLoS One       Date:  2014-09-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.